Taiwan-based Horien Biochemical Technology has announced a major double milestone in its global expansion strategy, i.e. the formal entry into the Thai market following Thai Food and Drug Administration (Thai FDA) Class 4 approvals for three advanced regenerative medical devices (Collagen Bone Graft Matrix; Collagen Matrix and Extracellular Membrane), alongside securing a prestigious US invention patent for its innovative biodegradable ureteral stent.
With its regulatory foundation fully established in Thailand, Horien is actively inviting qualified exclusive and strategic distribution partners to drive responsible market launch, clinician education, and long-term healthcare infrastructure development across the country.
Concurrently, the newly granted US patent underscores the company's world-class R&D capabilities in cross-linked biomaterials, further bolstering the company's reputation as an emerging global leader in regenerative medicine.
The company's top priority in Thailand is to establish sustainable partnerships with distributors who possess deep clinical reach and a strong commitment to professional medical education.
